Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Share-based Compensation: 2022-2025

Historic Share-based Compensation for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $1.2 million.

  • Corvus Pharmaceuticals' Share-based Compensation rose 70.16% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 65.27%. This contributed to the annual value of $3.0 million for FY2024, which is 39.87% up from last year.
  • Corvus Pharmaceuticals' Share-based Compensation amounted to $1.2 million in Q3 2025, which was down 0.56% from $1.3 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Share-based Compensation high stood at $1.3 million for Q2 2025, and its period low was $492,000 during Q1 2023.
  • Over the past 3 years, Corvus Pharmaceuticals' median Share-based Compensation value was $734,000 (recorded in 2024), while the average stood at $809,727.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Share-based Compensation tumbled by 33.42% in 2023 and then spiked by 81.57% in 2025.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Share-based Compensation stood at $620,000 in 2022, then dropped by 7.74% to $572,000 in 2023, then surged by 41.96% to $812,000 in 2024, then skyrocketed by 70.16% to $1.2 million in 2025.
  • Its Share-based Compensation was $1.2 million in Q3 2025, compared to $1.3 million in Q2 2025 and $1.3 million in Q1 2025.